Skip to Content

Akynzeo Approval History

FDA Approved: Yes (First approved October 10, 2014)
Brand name: Akynzeo
Generic name: netupitant and palonosetron
Dosage form: Capsules
Company: Helsinn Healthcare SA
Treatment for: Nausea/Vomiting, Chemotherapy Induced

Akynzeo (netupitant and palonosetron) is a substance P/neurokinin 1 (NK1) receptor antagonist and serotonin-3 (5-HT3) receptor antagonist fixed-dose combination indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Development History and FDA Approval Process for Akynzeo

DateArticle
Oct 10, 2014Approval FDA Approves Akynzeo (netupitant and palonosetron) for Chemotherapy-Induced Nausea and Vomiting
Jan 12, 2011FDA Agrees to Special Protocol Assessment (SPA) to Evaluate the Safety and Efficacy of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINV

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide